26
Participants
Start Date
April 30, 2013
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Methotrexate
"Subjects will receive Methotrexate as detailed in the Group description."
Ustekinumab
"Subjects will receive Ustekinumab as detailed in the Group description."
Etanercept
"Subjects will receive Etanercept as detailed in the Group description."
Adalimumab
"Subjects will receive Adalimumab as detailed in the Group description."
Acitretin
"Subjects will receive Acitretin as detailed in the Group description."
UVB Excimer Laser
"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
Narrowband UVB
"Subjects will receive Narrowband UVB as detailed in the Group description."
University Hospitals Cleveland Medical Center, Cleveland
National Psoriasis Foundation
OTHER
University Hospitals Cleveland Medical Center
OTHER